Armstrong AW, Papp KA, Zhuo J, Becker B, Zhong Y, Beaumont JL, DeRosa M, Kisa RM, Banerjee S, Strober B. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. J of Skin [Internet]. 2022Nov.16 [cited 2025Jan.9];6(6):s63. Available from: https://skin.dermsquared.com/skin/article/view/1818